{"id":"W2023275561","doi":"10.1002/cncr.20455","title":"Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone‐refractory prostate carcinoma","year":2004,"lang":"en","type":"article","venue":"Cancer","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Visual analogue scale; Prostate cancer; Doxorubicin; Prostate; Randomized controlled trial; Prospective cohort study; Chemotherapy; Toxicity; Cancer; Refractory (planetary science); Internal medicine; Surgery; Gastroenterology; Urology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001182315,0.0001619796,0.0005488041,0.00009885864,0.00005737421,0.00001581631,0.0002862038,0.00004279594,0.00007901222],"category_scores_gemma":[0.00004003564,0.0001071072,0.0001075039,0.000389453,0.0002767024,0.0001606272,0.00006762713,0.00008890491,0.00001034317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002159917,"about_ca_system_score_gemma":0.0001606189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004730626,"about_ca_topic_score_gemma":0.00002464264,"domain_scores_codex":[0.9981319,0.0002329254,0.0006729007,0.0002650898,0.0004246257,0.0002725506],"domain_scores_gemma":[0.9989912,0.0001210068,0.0003699292,0.0003768943,0.0001021307,0.00003885401],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3531803,0.001984859,0.00004820465,0.0002121498,0.00007934977,0.00005001297,0.008372354,0.001506202,0.6327246,0.0009995331,0.00005106408,0.0007912491],"study_design_scores_gemma":[0.6463203,0.0008952458,0.0004723686,0.0001597198,0.0001583758,0.000001308484,0.0005255888,0.0001671241,0.3502421,0.0009217045,0.000008611724,0.0001275648],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947616,0.001079418,0.00003109346,0.0001712226,0.0002466219,0.003388456,0.00003830438,0.00002605893,0.0002572495],"genre_scores_gemma":[0.9987993,0.0001395045,0.0001818024,0.00004469527,0.00003536405,0.0007335304,0.00000295235,0.00001471341,0.00004811952],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2931399,"threshold_uncertainty_score":0.4367706,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01137680616757674,"score_gpt":0.2714741012855239,"score_spread":0.2600972951179471,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}